SPOTLIGHT -
Dr. Patel Discusses Checkpoint Blockade in NSCLC
Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses checkpoint blockade in non–small cell lung cancer.
Read More
Dr. Patel on Combination Chemotherapy and Immunotherapy in Lung Cancer
Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses combination chemotherapy and immunotherapy in patients with lung cancer.
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
